Follow us on Twitter
twitter icon@FreshPatents

Cholesterol patents

Bulk PDF Downloads
      

This page is updated frequently with new Cholesterol-related patent applications.




 Composition patent thumbnailnew patent Composition
The present invention relates to one or more strains of lactobacilli and a cholesterol modifying agent (such as an oilgosaccharide) for use in modifying the absorption of cholesterol in an individual or the treatment of heart disease, diabetes or obesity.. .
Optibiotix Limited


 Modified irna agents patent thumbnailModified irna agents
The invention relates to irna agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the irna agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety.
Alnylam Pharmaceuticals, Inc.


 Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis patent thumbnailNuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g.
Virginia Commonwealth University


 Composition patent thumbnailComposition
The present invention relates to compositions for weight management comprising: a) a microbiome modifying component; b) a satiety modifying component; and c) a metabolic modifying component. The composition may also be used for the treatment of obesity, elevated cholesterol, diabetes, hypertension or heart disease..
Optibiotix Limited


 Stable powder formulation containing an anticholingeric agent patent thumbnailStable powder formulation containing an anticholingeric agent
A spray-dried powder formulation comprising particles that contain the following components i) to iii): i) anticholinergic agents, in particular at least one compound of formula 1, in which x− is a negatively charged anion, ii) at least one embedding material selected from the group consisting of mono- or disaccharides, oligosaccharides, polymers, sugar alcohols and cholesterol, and iii) an organic, physiologically acceptable, sterically demanding acid, selected from the group consisting of ascorbic acid, a monovalent, divalent or trivalent carboxylic acid, with the exception of amino carboxylic acids, to preferably fumaric acid, oxalic acid, or diacetic acid, and a fruit acid or culinary acid, preferably citric acid, tartaric acid, malic acid, lactic acid, acetic acid, α-hydroxycaprylic acid or gluconic acid.. .
Boehringer Ingelheim International Gmbh


 Compositions and methods for cardiovascular disease patent thumbnailCompositions and methods for cardiovascular disease
The present invention provides small molecule inhibitors of bmp signaling. These compounds may be used to reduce circulating levels of apob-100 or ldl.
The General Hospital Corporation


 Antimicrobial cationic polycarbonates patent thumbnailAntimicrobial cationic polycarbonates
Antimicrobial cationic polymers having one or two cationic polycarbonate chains were prepared by organocatalyzed ring opening polymerization. One antimicrobial cationic polymer has a polymer chain consisting essentially of cationic carbonate repeat units linked to one or two end groups.
Agency For Science, Technology And Research


 Antidiabetic tricyclic compounds patent thumbnailAntidiabetic tricyclic compounds
Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.


 Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety patent thumbnailSystemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety
The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating rna interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduced to a subject by systemic administration. Specifically, the invention relates to methods comprising the in vivo delivery of short interfering nucleic acid (sina) molecules that target a myostatin gene expressed by a subject, wherein the sina molecule is conjugated to a lipophilic moiety, such as cholesterol.
Sirna Therapeutics, Inc.


 Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases patent thumbnailAnti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (pcsk9), as well as therapeutic methods for use of such compounds to reduce ldl-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (cvd), including treatment of hypercholesterolemia. Examples of compounds include thiadiazole, isoxazole, 1,2,4-triazole, thiazole, indole, pyrazole, and pyrrolinone derivatives..
Shifa Biomedical Corporation


Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects


The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an mtp inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the mtp inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the mtp inhibitor to the subject.
The Trustees Of The University Of Pennsylvania


Combination liposomal pharmaceutical formulations


Docetaxel and doxorubicin can be formulated in liposomal pharmaceutical compositions. In various embodiments, the pharmaceutical compositions include (i) a first liposome type comprising a first lipid layer comprising an unsaturated phospholipid, cholesterol or a cholesterol derivative, dc-cholesterol, a cationic lipid, and preferably a pegylated phospholipid, and a first active pharmaceutical ingredient (api) comprising docetaxel in the first lipid layer; and (ii) a second liposome type comprising a second lipid layer, an aqueous interior, and a second api comprising doxorubicin crystallized in the aqueous interior, (iii) where the first liposome type does not comprise doxorubicin and the second liposome type does not comprise docetaxel.
Cureport, Inc.


Dual loaded liposomal pharmaceutical formulations


A pharmaceutical composition can include a plurality of liposomes comprising docetaxel and doxorubicin. In various embodiments, a liposome can include (i) an active pharmaceutical ingredient (api) comprising docetaxel and doxorubicin; (ii) a lipid layer comprising an unsaturated phospholipid, a cholesterol, a cationic lipid, and preferably a pegylated phospholipid; and (iii) an aqueous interior, wherein the docetaxel is in the lipid layer and the doxorubicin is crystallized in the aqueous interior.
Cureport, Inc.


Nucleic acid-lipopolymer compositions


Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10.
Clsn Laboratories, Inc.


Bioactive-rich concentrates and nutritive and therapeutic products containing same


This invention relates generally to the field of compositions for use as nutraceuticals, food additives or adjuncts to conventional drug therapies. In particular, the invention relates to compositions derived from natural oil sources which can be used for effective and inexpensive treatment of cardiovascular diseases, hypercholesterolemia, diabetes, cerebrovascular disease, neurological disorders, or liver abnormalities..

Methods of use to orally and topically treat acne and other skin conditions by administering a 19-nor containing vitamin d analog with or without a retinoid


Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin d analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(s)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(s)-2-methylene-1α,25-dihydroxyvitamin d3, 2-methylene-1α,25-dihydroxy-(17e)-17(20)-dehydro-19-nor-vitamin d3, 2-methylene-19-nor-(24r)-1α,25-dihydroxyvitamin d2, 2-methylene-(20r,25s)-19,26-dinor-1α,25-dihydroxyvitamin d3, 2-methylene-19-nor-1α-hydroxy-pregnacalciferol, 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol, (20r)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, 2-methylene-19-nor-(20s)-1α-hydroxy-trishomopregnacalciferol, 2-methylene-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnacalciferol, 2-methylene-(20s)-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnancalciferol, (2-(3′hydroxypropyl-1′,2′-idene)-19,23,24-trinor-(20s)-1α-hydroxyvitamin d3, 2-methylene-18,19-dinor-(20s)-1α,25-dihydroxyvitamin d3, a stereoisomer thereof, a prodrug thereof in oral compositions, a salt thereof, and/or a solute thereof.
Wisconsin Alumni Research Foundation


Reconstituted high density lipoproteins composition and uses thereof


A reconstituted high density lipoprotein composition including negatively charged phospholipids enhances cholesterol clearance, reduces inflammation and other anti-atherosclerotic actions.. .
Universite Pierre Et Marie Curie - Paris 6 (upmc)


Treatment of metabolic diseases by inhibtion of htr2a or htr3


The present invention relates to a method for preventing or treating a metabolic disease, which comprises inhibiting htr2a (5-hydroxytryptamine 2a receptor) or htr3a (5-hydroxytryptamine 3a receptor). The inhibition of htr3a leads to various advantageous efficacies for therapy of metabolic diseases, including resistance to obesity, decrease of lipid droplet size, increase of expression levels of thermogenic genes, increase of metabolic activities, increase of insulin sensitivity and decrease of ldl cholesterol and leptin..
Korea Advanced Institute Of Science And Technology


Liposome composition for cancer treatment


Disclosed is a liposomal composition for treatment of cancer, which includes at least one peg-phospholipid conjugated molecule, cholesterol, and at least one phospholipid.. .

Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Extracts of curcuma amada and uses thereof


The invention concerns carbon dioxide extracts of curcuma amada (mango ginger), including supercritical carbon dioxide extracts of c. Amada; methods for their production; compositions comprising the extracts; methods for treating or delaying the onset of conditions such as cell proliferation disorder (e.g., cancer), inflammation, infection, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, platelet hyper-aggregation, immune disorder such as autoimmune disorder, or neurodegenerative condition; and methods for inhibiting expression of bcl-2, bak, and p53 genes; inhibiting expression of the cox-2 and nf-kb genes, inhibiting production of phosphorylated target of rapamycin (tor), modulating amp-activated protein kinase (ampk), inhibiting protein kinase b (akt) signaling, modulating the ras/raf/mek/erk signaling pathway, and modulating the ras/pi3k/pten/akt/mtor signaling pathway.
Flavex Naturextrakte Gmbh


Agent for the selective adjustment of blood lipids


The invention relates to the medicine, namely to an agent for reducing the cholesterol and triglycerides in the blood plasma. The agent claimed comprises a nanocomposite that is a carbon-containing nanoparticles coated with the organic alkyl functional groups representing the residuals —c4h9, —c6h11, —c8h15, —c10h21, —c16h33, —c18h35.
Limited Liability Company "nanocor"


Preparation and uses of obeticholic acid


Or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a fxr mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing hdl cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis.

A probiotic composition comprising the novel isolated bacterial strain of brevibacterium casei ap9


The present invention discloses a novel isolated bacterial strain exhibiting probiotic properties. More particularly, the invention discloses a probiotic composition comprising brevibacterium casei ap9 mcc0012 having improved ph and bile tolerance and improved antimicrobial properties as well as possessing cholesterol reduction property..
Council Of Scientific & Industrial Research


Method for measuring cholesterol in high-density lipoprotein, and reagent for use in said method


Wherein r1 represents a linear or branched alkyl group having 8 to 22 carbon atoms or a linear or branched alkenyl group having 8 to 22 carbon atoms, r2, r3 and r4 are the same as or different from each other and represent a linear or branched alkyl group having 1 to 6 carbon atoms or a linear or branched alkenyl group having 2 to 6 carbon atoms, and x− represents an anion, and a polyanion.. .

Liposome for topical administration and application thereof


This invention provides a novel delivery means that enables efficient delivery of an active ingredient to a target cell. Such novel delivery means is a liposome for topical administration that consists of dioleylphosphatidylethanolamine (dope), phosphatidylcholine, and cationic lipid, that is not modified with peg, and that is free of cholesterol..
Delta-fly Pharma, Inc.


Targeting micrornas for metabolic disorders


Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level.
Eth Zurich


Aav-based treatment of cholesterol-related disorders


The invention in some aspects relates to methods and compositions for assessing the effectiveness of mirna inhibitors. In other aspects of the invention, methods and compositions for treating cholesterol related disorders are provided.
University Of Massachusetts


Rna/dna nanoparticle for sirna target-specific delivery and vehicle including the same


A rna/dna nanoparticle for delivering sirna where a rna transcript including at least one hairpin structure hybridizes dna-cholesterol conjugate and folate-dna conjugate including a complementary sequence to the rna transcript, and a composition including the rna/dna nanoparticle is provided. More specifically, because various sirna used for different applications can be contained in the rna/dna nanoparticle for delivering sirna at a high loading efficiency, and has stability to the outer attacks such as nuclease degradation.
Korea Institute Of Science And Technology


Antidiabetic tricyclic compounds


Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslip idemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.


Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells


cholesterol moieties are linked to specific ends of double-stranded rna, preferably a small, interfering (si)rna or to a dshybrid. The dshybrid has one strand comprised of dna and one strand comprised of rna.
Marina Biotech, Inc.


Dietary fiber containing materials comprising low molecular weight glucan


A dietary fiber material obtained by using enzymes to digest cereal grains. The enzymes substantially hydrolyze any starch occurring in the cereal grain into small molecules but only partially hydrolyze β-glucan molecules.
Cargill, Incorporated


Compositions and therapeutic methods for accelerated plaque regression


The invention comprises methods for treating and/or preventing cardiovascular, cholesterol, and lipid related disorders, including atherosclerosis, through co-administration of therapeutically effective amounts of rvx-208 or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof. The invention further provides compositions comprising a therapeutically effective amount of rvx-208 or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of rosuvastatin or a pharmaceutically acceptable salt thereof..
Resverlogix Corp.


Therapeutic agent for dyslipidemia


This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemia states, such as hyper-ldl cholesterolemia, in mammals, including humans. This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, said drug composition comprising the following: (r)-2-[3-[[n-(benzoxazole-2-yl)-n-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate of either; and an omega-3 fatty acid or an ester derivative of an ω-3 fatty acid..
Kowa Company, Ltd.


Cholesterol ester-depleting nanomedicine for non-toxic cancer chemotherapy


The present invention provides a formulation for reducing the hydrophobicity of acat-1 inhibitors. Methods for using the formulation of the present invention are also provided..
Purdue Research Foundation


Composition for treating hyperlipidemia comprising oxyntomodulin derivative


The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate glp-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio.
Hanmi Pharm. Co., Ltd.


Astragalus membranaceus seed raw oil, refined oil, preparation method therefor and use thereof


The invention belongs to the field of traditional chinese medicine (tcm), and in particular relates to an astragalus membranaceus seed raw oil and refined oil extracted from astragalus membranaceus seeds by using a supercritical extraction method, and to a use thereof in the preparation of health-care products. The astragalus membranaceus seed raw oil is obtained by supercritical co2 fluid extraction on the astragalus membranaceus seeds; and the astragalus membranaceus seed refined oil is obtained by physically refining the astragalus membranaceus seed raw oil.
Shanxi Zhendong Pharmaceutical Co. Ltd.


Animal feed including cationic cholesterol additive and related methods


Methods and feed compositions for increasing health of agricultural animals incude administering a cationic cholesterol additive through the diet of the animal, such as through solid feed or drinking water of the animals. The method includes feeding an animal a diet comprised of a cationic cholesterol additive, such as a compound with a sterol backbone and a plurality of cationic groups attached thereto.
Brigham Young University


Method for preparing nanoemulsion


Provided is a method for preparing a nanoemulsion, including mixing an oil phase part (a) containing a ceramide or derivative thereof, cholesterol, non-ionic surfactant, phospholipid and a polyol, a perfume part (b) containing a perfume ingredient, non-ionic surfactant and an alcohol, and an aqueous phase part (c) containing the other water-soluble active ingredients. When a nanoemulsion is obtained by the method, it is possible to reduce processing time and cost since a non-ionic surfactant is used without a high-pressure emulsification process, and the obtained nanoemulsion is more stable against a change in temperature than the other solubilized formulations..
Cosmax, Inc.


Nutritional and exercise plan based on a person's individual genetic apo e genotype


A nutritional plan based on a person's individual genetic apo e genotype, which has been shown to be the number one gene affecting diet, cholesterol, heart disease, vascular dementia, alzheimer's disease, and chronic illness, possibly autism, parkinson's disease, and other neurological diseases, and that focuses on the right percentages of macronutrients for each individual's genetic type, is disclosed.. .

Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Method of enhancing mir-185 expression to reduce low density lipoprotein/cholesterol accumulation in a cell


The present invention provides a method of quantifying mir-185 as a potential biomarker in lipid disorder or cardiovascular diseases in human. The present invention also provides a method of modulating mir-185 in regulating ldl and cholesterol metabolism in cells.
Medical Diagnostic Laboratories, Llc


Methods of using interleukin-10 for treating diseases and disorders


Methods of treating subjects having diseases, disorders, or conditions, including disorders associated with cholesterol homeostasis, responsive to il-10, including methods of administration and dosing regimens associated therewith, are provided, more particularly, the present disclosure relates to optimized dosing parameters to achieve and maintain efficacy in the treatment and/or prevention of metabolic diseases, disorders and conditions in a subject, while minimizing the adverse effects associated therewith. Particular embodiments are directed to the treatment and/or prevention of abnormally high levels of cholesterol and/or manifestation(s) of hypercholesterolemia in as subject..
Armo Biosciences, Inc.


Rett syndrome and treatments therefore


The present invention provides new strategies for the treatment of rett syndrome and other mecp2-associated disorders, including for the identification and/or characterization of useful therapeutic modalities and/or for the stratification of rett syndrome patients to identify those more or less likely to respond to a particular therapy. In some embodiments, the present invention defines certain components of metabolic pathways, and particularly of lipid and/or cholesterol metabolism (e.g., biosynthesis) pathways, most particularly of lipid and/or cholesterol metabolism (e.g., biosynthesis) pathways in the brain, as targets useful in the identification and/or characterization of potential rett syndrome treatment agents.
Baylor College Of Medicine


Ketone bodies and ketone body esters as blood lipid lowering agents


The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic β-hydroxybutyrate or d-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or d-β-hydroxybutyrate, esters of d-β-hydroxybutyrate, oligomers of d-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or r-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject.
Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services


Agents and methods for inhibiting mir-148a for the modulation of cholesterol levels


Elevated blood levels of low-density lipoprotein-cholesterol (ldl-c, or “bad” cholesterol) are strongly linked to circulatory disorders, e.g. Cardiovascular disease such as atherosclerosis, angina, coronary heart disease, heart attack, stroke, etc.

Bicyclic ureas and thiadiazolidine-1, 1-dioxides as cetp inhibitors


Compounds having the structure of formula i, including pharmaceutically acceptable salts of the compounds, wherein x is —c(═o) or —s(o)2—, are cetp inhibitors and are useful for raising hdl-cholesterol, reducing ldl-cholesterol, and for treating or preventing atherosclerosis.. .

Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid


Novel salt forms of [r—(r*,r*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid characterized by their x-ray powder diffraction pattern and solid-state nmr spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and alzheimer's disease.. .

Method of pretreatment of sample for quantitating cholesterol and quantitating cholesterol in specific lipoproteins by using the same


A method of a pretreatment of a sample for quantitating cholesterol characterized by, before measuring cholesterol contained in specific lipoproteins, treating the sample containing lipoproteins with an enzyme, the substrate of which is free cholesterol, optionally together with a reaction accelerator; a method for quantitating cholesterol in specific lipoproteins by using the above method; and a kit for quantitating cholesterol in specific lipoproteins to be used in the above quantification method. By using this quantification method, cholesterol in a specific fraction can be conveniently, accurately and efficiently quantitated fundamentally without resort to polyanion, etc.

Preparation and uses of obeticholic acid


Or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a fxr mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing hdl cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis.

Use of nutritional compositions with phospholipid sphingolipid and cholesterol


A nutritional composition comprising phospholipids, sphingolipids and cholesterol for the prevention of obesity and/or diabetes is provided.. .

Beverage lowering serum cholesterol


A beverage comprising protein, plant sterol ester and/or plant stanol ester, a fruit and/or vegetable preparation, and a stabiliser.. .

Method and reagent for quantifying cholesterol in high density lipoprotein 3


Disclosed are a method and a reagent for quantifying hdl3 in a test sample without requiring laborious operations. The method for quantifying cholesterol in high-density lipoprotein 3 comprises reacting a test sample with one or more surfactants which react specifically with high-density lipoprotein 3, and quantifying cholesterol.
Denka Seiken Co., Ltd.


Fibronectin based scaffold domain proteins that bind pcsk9


The present invention relates to fibronectin based scaffold domain proteins that bind pcsk9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases.
Bristol-myers Squibb Company


Lactococcus lactis strains for producing bioactive peptides having anti-hypertensive and cholesterol-lowering effects


New lactococcus lactis strains, nrrl b-50571 and nrrl b-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower ldl-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation..
Centro De Investigación En Alimentación Y Desarrollo, A.c. (ciad)


Non-flushing niacin analogues, and methods of use thereof


One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
Trustees Of Tufts College


Nutraceutical composition for the treatment of excess weight and moderate hypercholesterolemia/dysglycemia


A nutraceutical composition is provided for the treatment of excess weight and moderate hypercholesterolemia/dysglycemia, comprising: berberine, monacolin k, 1-deoxynojirimycin (dnj).. .
Akademy Pharma S.r.l.


Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions


The present invention relates to methods of treating lipid disorders, lipid-related disorders or conditions, obesity and obesity-related disorders using nitrated lipids. In particular, the methods comprise administering effective amounts of nitrated fatty acids or esters thereof in order to reduce one or more of triglycerides, free fatty acids, body weight, cholesterol, urine protein excretion and oxidative stress or increase the level of plasma hdl in a subject..
The University Of Utah Research Foundation


Adjuvant compositions and related methods


The present disclosure provides for an adjuvant composition that is suited for injectable as well as transdermal administration. The adjuvant composition generally comprises a lipophile, a polymer of acrylic or methacrylic acid, saline, cholesterol, a saponin, and sodium hydroxide.
Vaxliant, Llc


Novel strain of bifidobacterium animalis subsp. lactis cect 8145 and use thereof for the treatment and/or prevention of excess weight and obesity and associated diseases


The invention is applicable within the food and pharmaceutical industry. More specifically, it relates to a novel strain of the species bifidobacterium animalis subsp.
Biopolis, S.l.


Compositions and their use for removing cholesterol


The invention is directed to compositions that function to remove cholesterol from a mammal suffering from an elevated cholesterol level. The composition includes a polysaccharide having attached thereto at least one cyclic oligosaccharide.
Cornell University


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Variable color transparent lip balm and preparation method thereof


The present invention provides a variable color transparent lip balm, consisting of following components by weight percent: 4.0 to 5.0% by weight of dibutyl lauroyl glutamide, 2.0 to 3.0% by weight of polyamide-3, 15.0 to 20.0% by weight of bis-stearyl ethylenediamine/neopentyl glycol/stearyl hydrogenated dimer dilinoleate copolymer, 46.65 to 49.60% by weight of c12-15 alkyl benzoate, 1.0 to 3.0% by weight of heptyl undecylenate, 9.0 to 11.0% by weight of c10-30 cholesterol/lanosterol esters, 10.0 to 15.0% by weight of hydrogenated c6-20 polyolefin, 1.5 to 2.5% by weight of dextrin isostearate, 0.05 to 0.1% by weight of eosin yellowish and 0 to 0.8% by weight of excipient. The transparent lip balm of the present invention has good transparency, and excellent variable color effect..
Guangzhou Sheencolor Cosmetics Co., Ltd.


Edible composition suitable for lowering serum cholesterol


The present invention relates to an edible composition comprising plant sterol ester and/or plant stanol ester and triglyceride fat usable for lowering serum ldl cholesterol. The composition further comprises oligosaccharides and sugars.
Raisio Nutrition Ltd


Cardiovascular disease risk assessment


The invention provides improved methods for analyzing cardiovascular disease risk. According to the invention, an algorithm that considers ldl and hdl subfractions, along with lp(a) provides significant improvement in predicting cvd versus standard assays that include standard risk factors.
Boston Heart Diagnostic Corporation


Oligonucleotide conjugates


The present invention relates to oligomeric compounds and conjugates thereof that target proprotein convertase subtilisin/kexin type 9 (pcsk9) pcsk9 mrna in a cell, leading to reduced expression of pcsk9. Reduction of pcsk9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders..
Roche Innovation Center Copenhagen A/s


Methods for treating high cardiovascular risk patients with hypercholesterolemia


The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a pcsk9 inhibitor.
Regeneron Pharmaceuticals, Inc.


Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)


The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to patients with heterozygous familial hypercholesterolemia a pharmaceutical composition comprising a pcsk9 inhibitor.
Regeneron Pharmaceuticals, Inc.


Compositions and methods of altering cholesterol levels


The present invention relates to compositions, methods and kits using polynucleotides, primary transcripts and mmrna molecules. The present invention also relates to compositions and methods for altering cholesterol levels using polynucleotides, primary transcripts and mmrna molecules..
Moderna Therapeutics, Inc.


Composition containing composite extract of rehmannia glutinosa and pueraria lobata for preventing or treating menopausal symptoms


The present invention relates to a composition and functional health food containing a composite extract of rehmannia glutinosa and pueraria lobata for preventing or treating menopausal symptoms; and a method for preventing or treating menopausal symptoms by administering the composite extract. The composite extract of rehmannia glutinosa and pueraria lobata of the present invention can ameliorate weight increase, which is the representative symptom of menopausal women, and can effectively improve osteoporosis and blood cholesterol.
University-industry Cooperation Group Of Kyung Hee University


Use of cilastatin to reduce the nephrotoxicity of different compounds


Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts.
Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon


Ship inhibition to combat obesity


The present invention relates to the use of ship1 inhibitors and pan-ship1/2 inhibitors in various methods, including, without limitation: (i) a method to treat obesity or reduce body fat of an obese subject; (ii) a method to limit bone development in a subject suffering from an osteopetrotic or sclerotic disease; (iii) a method to treat or prevent diabetes; (iv) a method to reduce glucose intolerance or insulin resistance; and (v) a method to lower cholesterol.. .
The Research Foundation For The State University New York


Process and composition for stabilization of vulnerable plaque utilizing a combination of a statin and omega 3 fatty acids


A composition and a method of treatment utilizing a combination of statins (or hmg-coa reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme hmg-coa reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of eicosapentaenoic acid (epa), docosapentaenoic acid (dpa) and docosahexaenoic acid (dha) in a weight ratio of epa:dha of from 5.7 to 6.3, wherein the sum of the epa, dha and dpa represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition, the compositions and method designed to stabilize vulnerable plaque while mediating omega-3 deficiencies in individuals in need thereof.. .
Pivotal Therapeutics Inc.


Angiotensin peptide and pharmaceutical compositions for disease treatment


The present invention relates to the peptide (arg0) n-angiotensin-(1-7) [(arg0) n-ang-(1-7)], where n is 1 to 10 (xaa-asp-arg-val-tyr-ile-his-pro; seq id no:1 where xaa represents 1 to 10 l-arg residues), which is produced by inserting at least one arginine amino acid at the amino terminal position of ang-(1-7), as well as pharmaceutical compositions containing this peptide and the use thereof for the treatment or prevention of diseases or disorders that are due or associated with reduced nitric oxide production. Non-limiting examples of these diseases or disorders are cardiopulmonary and liver diseases, vascular disorders, metabolic disorders, neural disorders, genito-urinary tract disorders, skeletal muscle disorders, kidney disorders, skin disorders, alopecia or tumors.
Universidade Federal De Minas Gerais - Ufmg


Bile salt hydrolase bsh1 for regulating weight gain, serum cholesterol levels, and liver triglycerides in a mammal; bacteria strains expressing bsh1 variants


A non-therapeutic method of reducing weight gain, serum cholesterol levels, or liver triglyceride levels, in a non-obese mammal, comprises the step of administering to the gut of a mammal an effective amount of a bacteria expressing a bsh1 enzyme of sequence id no: 1, or a functional variant thereof; a bsh1 enzyme of sequence id no: 1, or a functional variant thereof for use as a medicament; isolated bacterial strains expressing functional variants of bsh1.. .
University College Cork, National University Of Ireland


Compositions and methods for regulating angiogenesis and cholesterol and treating dyslipidemia, atherosclerosis, cancer and inflammatory conditions


The invention provides pharmaceutical compounds and formulations comprising nucleic acids and polypeptides for regulating (including upregulating or inhibiting) the expression of apoa-1 binding protein (apoaibp, aibp, or ai-bp), and methods for making and using them. In alternative embodiments, apoaibp-inhibiting pharmaceutical compositions and formulations of the invention are administered to an individual in need thereof in an amount sufficient to stimulate tissue revascularization, e.g., supporting or stimulating revascularization of heart tissue, e.g., after a cardiac ischemia.
The Regents Of The University Of California


Bmp inhibitors and methods of use thereof


The present invention provides small molecule inhibitors of bmp signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with bmp signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
The General Hospital Corporation


Inhibitors of cholesterol ester transfer protein


The invention relates to novel oxazolidinones their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering cholesterol ester transfer protein inhibitors..
Concert Pharmaceuticals, Inc.






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cholesterol for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cholesterol with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.7365

5115

1 - 1 - 102